Smoldering Myeloma: The Treatment Issue Is Getting Trickier David Brzostowicki

https://www.medscape.com/viewarticle/smoldering-myeloma-treatment-issue-getting-trickier-2026a1000p2y The landscape around high-risk smoldering multiple myeloma has been shifting quickly in the past year. Last November, the FDA approved the monoclonal antibody daratumumab (Darzalex Faspro) based on the phase 3 AQUILA trial, which showed the drug delayed progression compared with active monitoring. Since then, early-phase trials of CAR T-cell therapy and bispecific antibodies have reported deep remissions in the smoldering setting — with some investigators raising the possibility of a cure.